Aurinia Pharmaceuticals (AUPH) Cash from Investing Activities (2020 - 2026)

Aurinia Pharmaceuticals' Cash from Investing Activities history runs 7 years deep, the most recent figure standing at -$18.1 million for Q1 2026.

• Quarterly Cash from Investing Activities fell 158.26% year-over-year to -$18.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$81.9 million (down 488.78% YoY) and the FY2025 annual result came in at -$32.8 million, down 183.46% from the prior year.
• Cash from Investing Activities was -$18.1 million for Q1 2026 at Aurinia Pharmaceuticals, up from -$36.8 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $49.2 million in Q1 2024 and bottomed at -$53.0 million in Q1 2022.
• A 5-year average of -$4.6 million and a median of -$10.6 million in 2024 frame the typical range for Cash from Investing Activities.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities jumped 2631.8% — and 2024, when it sank 588.69%.
• Aurinia Pharmaceuticals' Cash from Investing Activities stood at -$3.0 million in 2022, then slumped by 107.32% to -$6.3 million in 2023, then surged by 726.87% to $39.2 million in 2024, then slumped by 193.71% to -$36.8 million in 2025, then surged by 50.81% to -$18.1 million in 2026.
• Business Quant data shows AUPH's Cash from Investing Activities at -$18.1 million in Q1 2026, -$36.8 million in Q4 2025, and -$13.8 million in Q3 2025.